This gamified, CME-accredited OncoBlast activity immerses learners in the evolving landscape of molecular oncology. Through interactive challenges, participants will identify common molecular abnormalities across multiple cancer types, interpret biomarker results, and apply next-generation sequencing data to guide personalized treatment strategies. The course also explores emerging targeted therapies, testing methodologies, and the clinical impact of novel agents in development—equipping clinicians with the tools to deliver precision cancer care.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Marianne Dubard-Gault (MD, MC, Swedish Hereditary Cancer Clinic)
Dr Dubard-Gault is a cancer genetics and an early detection doctor. She trained in preventive medicine and oncology in France, in medicine at University of Pennsylvania in Philly, and in genetics at MSKCC in New York. She was at UW/Fred Hutch for almost 5 years, and she is now the medical director of cancer genetics and high-risk services at Providence-Swedish. In the clinic, she focuses on detecting a predisposition to cancer by offering genetic testing. Then, she helps patients launch a screening and early detection plan, so they and their family members are empowered to change their risk of developing certain cancers, and benefit from potentially life-saving interventions. As a researcher, she is a key member of the Initiative for Prevention and Early Detection Program at the Paul G. Allen Research Center. She is a co-investigator on multiple protocols to advance knowledge in hereditary syndromes. She is interested in continuing to expand access to genetics studies, early detection, and cancer prevention clinical trials.
Disclosure
Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months. Financial relationships:
- Medical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Target Audience
- Identify key molecular alterations across common cancers and determine the appropriate timing and methodology for biomarker testing.
- Interpret results from next-generation sequencing and other biomarker assays to guide personalized, targeted treatment strategies.
- Develop evidence-based, molecularly guided treatment plans for patients with various malignancies.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: